Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Mycobacterium tuberculosis | 11 | 2020 | 1164 | 1.59 | Why? |
| Tuberculosis | 14 | 2021 | 2895 | 1.58 | Why? |
| Latent Tuberculosis | 5 | 2020 | 324 | 1.04 | Why? |
| Antitubercular Agents | 9 | 2019 | 775 | 0.84 | Why? |
| Interferon-gamma Release Tests | 4 | 2020 | 253 | 0.82 | Why? |
| GATA2 Transcription Factor | 1 | 2018 | 13 | 0.75 | Why? |
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2018 | 39 | 0.75 | Why? |
| Nontuberculous Mycobacteria | 1 | 2018 | 114 | 0.66 | Why? |
| Tuberculosis, Multidrug-Resistant | 6 | 2019 | 433 | 0.64 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 167 | 0.59 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 66 | 0.56 | Why? |
| Pyrazinamide | 3 | 2019 | 38 | 0.43 | Why? |
| Interferon-gamma | 2 | 2017 | 2711 | 0.37 | Why? |
| HIV Infections | 8 | 2020 | 11620 | 0.36 | Why? |
| Rifampin | 3 | 2019 | 276 | 0.35 | Why? |
| Clinical Deterioration | 2 | 2021 | 473 | 0.31 | Why? |
| Antigens, Bacterial | 2 | 2019 | 330 | 0.29 | Why? |
| Coinfection | 3 | 2020 | 6820 | 0.28 | Why? |
| BCG Vaccine | 3 | 2020 | 1137 | 0.26 | Why? |
| Tuberculosis, Pulmonary | 3 | 2019 | 1171 | 0.26 | Why? |
| Isoniazid | 3 | 2019 | 105 | 0.26 | Why? |
| Ethambutol | 2 | 2019 | 34 | 0.26 | Why? |
| Influenza Vaccines | 1 | 2018 | 2941 | 0.22 | Why? |
| Contact Tracing | 2 | 2021 | 8448 | 0.22 | Why? |
| Pseudomonas Infections | 1 | 2005 | 425 | 0.22 | Why? |
| Pseudomonas aeruginosa | 1 | 2005 | 652 | 0.21 | Why? |
| Tuberculosis, Ocular | 1 | 2019 | 14 | 0.20 | Why? |
| United Kingdom | 9 | 2021 | 18046 | 0.20 | Why? |
| Bone Marrow Examination | 1 | 2018 | 24 | 0.19 | Why? |
| Levofloxacin | 1 | 2019 | 115 | 0.19 | Why? |
| Capreomycin | 1 | 2017 | 2 | 0.18 | Why? |
| Germ-Line Mutation | 1 | 2018 | 86 | 0.18 | Why? |
| Mycobacterium avium Complex | 1 | 2018 | 61 | 0.18 | Why? |
| HIV Seronegativity | 1 | 2018 | 112 | 0.18 | Why? |
| Fluoroquinolones | 1 | 2019 | 235 | 0.18 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2018 | 59 | 0.17 | Why? |
| Amikacin | 1 | 2017 | 62 | 0.17 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.17 | Why? |
| Vaccination | 5 | 2021 | 19050 | 0.17 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.17 | Why? |
| Tuberculin Test | 1 | 2017 | 141 | 0.16 | Why? |
| HIV-1 | 2 | 2015 | 3365 | 0.16 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.15 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.15 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2015 | 952 | 0.15 | Why? |
| London | 5 | 2020 | 2166 | 0.14 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.14 | Why? |
| Lung Diseases | 2 | 2018 | 2361 | 0.14 | Why? |
| Hearing Loss | 1 | 2017 | 225 | 0.13 | Why? |
| Influenza, Human | 2 | 2018 | 10779 | 0.13 | Why? |
| Substance Abuse, Intravenous | 1 | 2017 | 411 | 0.12 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.12 | Why? |
| Sputum | 2 | 2018 | 1720 | 0.12 | Why? |
| Diagnostic Imaging | 1 | 2020 | 1044 | 0.12 | Why? |
| Drug Resistance, Bacterial | 2 | 2018 | 1414 | 0.11 | Why? |
| Humans | 40 | 2021 | 930598 | 0.11 | Why? |
| Africa | 1 | 2020 | 2986 | 0.11 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.11 | Why? |
| Lymphocyte Count | 2 | 2017 | 4758 | 0.11 | Why? |
| Lung Diseases, Interstitial | 1 | 2021 | 1476 | 0.10 | Why? |
| Hepatitis B | 1 | 2018 | 888 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Lung | 3 | 2020 | 31049 | 0.10 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.09 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.09 | Why? |
| Skin Diseases | 1 | 2005 | 2509 | 0.09 | Why? |
| Sepsis | 1 | 2005 | 3517 | 0.09 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.09 | Why? |
| Northern Ireland | 2 | 2018 | 228 | 0.08 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Homeless Persons | 1 | 2018 | 1171 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Piperacillin | 1 | 2005 | 63 | 0.08 | Why? |
| England | 4 | 2019 | 5116 | 0.08 | Why? |
| Male | 20 | 2021 | 367725 | 0.08 | Why? |
| Penicillanic Acid | 1 | 2005 | 58 | 0.08 | Why? |
| Gentamicins | 1 | 2005 | 76 | 0.08 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.07 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.07 | Why? |
| Female | 19 | 2021 | 380317 | 0.07 | Why? |
| Microbial Sensitivity Tests | 3 | 2019 | 2886 | 0.07 | Why? |
| Adult | 16 | 2021 | 244371 | 0.07 | Why? |
| Wales | 2 | 2018 | 758 | 0.07 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.07 | Why? |
| Developing Countries | 1 | 2020 | 4283 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Mental Health | 2 | 2021 | 15770 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Resilience, Psychological | 1 | 2018 | 2329 | 0.06 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.06 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.06 | Why? |
| CD4 Lymphocyte Count | 1 | 2006 | 1517 | 0.05 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.05 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Iatrogenic Disease | 1 | 2021 | 304 | 0.05 | Why? |
| Community-Acquired Infections | 1 | 2011 | 2328 | 0.05 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.04 | Why? |
| United Nations | 1 | 2021 | 367 | 0.04 | Why? |
| Treatment Outcome | 3 | 2017 | 51732 | 0.04 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2006 | 2309 | 0.04 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| World Health Organization | 2 | 2019 | 4213 | 0.04 | Why? |
| Retrospective Studies | 5 | 2019 | 105322 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.04 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Patient Health Questionnaire | 1 | 2018 | 625 | 0.04 | Why? |
| Hypokalemia | 1 | 2017 | 195 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.04 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.04 | Why? |
| Drug Resistance, Microbial | 1 | 2019 | 419 | 0.04 | Why? |
| Genome, Bacterial | 1 | 2018 | 446 | 0.04 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.04 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2020 | 53120 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.03 | Why? |
| School Health Services | 1 | 2018 | 294 | 0.03 | Why? |
| Depression | 1 | 2018 | 14116 | 0.03 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.03 | Why? |
| Data Accuracy | 1 | 2019 | 715 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.03 | Why? |
| Anti-HIV Agents | 1 | 2005 | 2209 | 0.03 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 451 | 0.03 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.03 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Aged | 7 | 2021 | 215776 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2005 | 4545 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Respiratory Tract Infections | 1 | 2011 | 6817 | 0.03 | Why? |
| Bacterial Proteins | 1 | 2019 | 1318 | 0.02 | Why? |
| Glucocorticoids | 1 | 2005 | 4431 | 0.02 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2006 | 6670 | 0.02 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 3832 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Transients and Migrants | 1 | 2020 | 1468 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Medication Adherence | 1 | 2016 | 1270 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Minority Groups | 1 | 2017 | 1631 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2019 | 2844 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Clinical Protocols | 1 | 2016 | 2734 | 0.02 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Child | 3 | 2018 | 70012 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Anti-Bacterial Agents | 1 | 2005 | 10083 | 0.02 | Why? |
| Renal Dialysis | 1 | 2020 | 4358 | 0.02 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Disease Management | 1 | 2016 | 6841 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Pneumonia | 1 | 2011 | 5652 | 0.01 | Why? |
Lipman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(185)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(155)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_